OCULNasdaqPharmaceutical PreparationsFiscal year ends December 31
OCULAR THERAPEUTIX, INC
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 3, 2026
$6.29−0.58 (-8.44%)
Close on Oct 19, 2026
- Market cap
- $1.41B
- P/E (TTM)
- –
- Dividend yield
- –
OCULAR THERAPEUTIX, INC revenue by segment
By business segment
By product or service
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Product revenue, net | $52.05M | $51.97M | $51.82M | $55.59M | $56.40M | $59.38M | $63.46M | $61.12M | $60.72M | $59.37M | $57.87M | $57.10M | 100.0% | -7.7% |
| Collaboration revenue | – | – | $128.00K | $190.00K | $268.00K | $266.00K | $262.00K | $323.00K | $376.00K | $471.00K | $573.00K | $621.00K | – | – |
By region
From the segment and revenue-disaggregation notes of Ocular Therapeutix's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.